

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

In vivo bioequivalence study of Quetiapine 25 mg tablet manufactured by Hakim Co. compared with innovator product

Protocol summary

Study aim

En In vivo fasted-state bioequivalence study of Quetiapine 25 mg tablet

Design

The clinical trial has control and test groups with crossover, randomized design, without blinding. Twenty-four healthy male volunteers will participate randomly in the study as two twelve-person study groups. Each volunteer will receive a single dose of drug in two periods. In one period the test formulation and in another period the reference formulation. Therefore, each volunteer will be his own "Control". To randomly assign participants in two groups, the lottery method will be used.

Settings and conduct

After oral administration of one 25 mg tablet, the blood samples will be collected in predetermined time intervals up to 24 hours. The samples will be stored in freezer -4 degrees centigrade until analysis. The concentration of drug in blood samples will be measured by liquid chromatography equipped with mass spectroscopy detector. The study will be performed in Faculty of Pharmacy, Tabriz University of Medical Sciences. This study will be conducted without blinding.

Participants/Inclusion and exclusion criteria

Inclusion criteria: General Health (in terms of Liver, Heart and Kidney), Age (18-59 years old) Exclusion criteria: Smoking, History of cardiovascular, liver and kidney disease, Pregnancy, Alcohol and drug addiction, History of drug allergy.

Intervention groups

Intervention group will receive a single oral dose of test product (Quetiapine 25 mg tablet of Hakim Co.) and Control group will receive a single dose of reference product (Quetiapine 25 mg tablet of Astrazeneca). Blood samples will be taken for 24 hours at the mentioned time points and the plasma will be stored in freezer until analysis. In both groups, breakfast and lunch will be served two and six hours after drug administration,

respectively)

Main outcome variables

Drug plasma concentration

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20210519051345N21**

Registration date: **2022-12-22, 1401/10/01**

Registration timing: **prospective**

Last update: **2022-12-22, 1401/10/01**

Update count: **0**

Registration date

2022-12-22, 1401/10/01

Registrant information

Name

Parvin Zakeri-Milani

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 41 3334 8801

Email address

pzakeri@tbzmed.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-01-20, 1401/10/30

Expected recruitment end date

2023-06-21, 1402/03/31

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date
empty

Scientific title
In vivo bioequivalence study of Quetiapine 25 mg tablet manufactured by Hakim Co. compared with innovator product

Public title
Investigating the in vivo bioequivalence of Quetiapine 25 mg tablet

Purpose
Other

Inclusion/Exclusion criteria
Inclusion criteria:
General Health (in terms of Liver, Heart and Kidney)
Exclusion criteria:
Smoking History of cardiovascular disease, liver and kidney disease Pregnancy Alcohol and drug addiction History of drug allergy

Age
From **18 years** old to **59 years** old

Gender
Male

Phase
Bioequivalence

Groups that have been masked
No information

Sample size
Target sample size: **24**

Randomization (investigator's opinion)
Randomized

Randomization description
To randomly assign participants in two groups, 24 cards with numbers 1 to 24 will be used in closed envelopes that are arranged irregularly. Each candidate will pick up an envelope. Numbers 1-12 will be in group A and numbers 13-24 will be in group B. Group A will receive intervention 1 and group B will receive intervention 2, and after the first period, the interventions of both groups will change for the second period.

Blinding (investigator's opinion)
Not blinded

Blinding description

Placebo
Not used

Assignment
Crossover

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Biomedical Research Committe, Tabriz University of

Medical Sciences
Street address
Faculty of Pharmacy, University of Medical Sciences, Golgasht st., Attar Neishaboori st.
City
Tabriz
Province
East Azarbaijan
Postal code
51664-14766
Approval date
2022-12-19, 1401/09/28
Ethics committee reference number
IR.TBZMED.REC.1401.851

Health conditions studied

1

Description of health condition studied

In the present study, the products will be administered to healthy volunteers.

ICD-10 code

ICD-10 code description

Primary outcomes

1

Description

Plasma concentration of drug

Timepoint

0.33-72 hours in predetermined time intervals after drug administration

Method of measurement

HPLC (High performance liquid chromatography)

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: Intervention group: Intervention group will receive a single oral dose of test product (Quetiapine 25 mg tablet manufactured by Hakim Co.) in fasted state. Blood samples will be collected for 24 hours at the mentioned times after drug administration and the concentration of drug in blood samples will be stored in freezer until analysis. Breakfast and lunch will be served two and six hours after drug administration, respectively.

Category

Treatment - Drugs

2

Description

Control group: Control group will receive a single oral dose of reference product (Quetiapine 25 mg tablet

manufactured by Astrazeneca, Switzerland) in fasted state. Blood samples will be collected for 24 hours at the mentioned times after drug administration and the concentration of drug in blood samples will be stored in freezer until analysis. Breakfast and lunch will be served two and six hours after drug administration, respectively.

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Tabriz University of Medical Sciences

Full name of responsible person

Parvin Zakeri-Milani

Street address

Faculty of Pharmacy ,University of Medical Sciences,
Attar Neishaboori st., Golgasht st.,

City

Tabriz

Province

East Azarbaijan

Postal code

51664-14766

Phone

+98 41 3334 8801

Email

pzakeri@tbzmed.ac.ir

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Tabriz University of Medical Sciences

Full name of responsible person

Parviz Shahabi

Street address

No.2 Central Building, 3rd Floor, Daneshgah st. Tabriz
University of Medical Science

City

Tabriz

Province

East Azarbaijan

Postal code

51664-14766

Phone

+98 41 3334 8801

Email

shahabip@tbzmed.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

No

Title of funding source

Hakim Pharmaceutical Co.

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Industry

Person responsible for general inquiries**Contact****Name of organization / entity**

Tabriz University of Medical Sciences

Full name of responsible person

Parvin Zakeri-Milani

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Golgasht, Attar Neishabouri st, University of Medical
Sciences, Faculty of Pharmacy

City

Tabriz

Province

East Azarbaijan

Postal code

51664-14766

Phone

+98 41 3334 8801

Fax

+98 41 3334 4798

Email

pzakeri@tbzmed.ac.ir

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Tabriz University of Medical Sciences

Full name of responsible person

Parvin Zakeri-Milani

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Golgasht, Attar Neishabouri st, University of Medical
Sciences, Faculty of Pharmacy

City

Tabriz

Province

East Azarbaijan

Postal code

51664-14766

Phone

+98 41 3334 8801

Fax

+98 41 3334 4798

Email

pzakeri@tbzmed.ac.ir

51664-14766

Phone

+98 41 3334 8801

Fax

+98 41 3334 4798

Email

pzakeri@tbzmed.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Parvin Zakeri-Milani

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Golgasht, Attar Neishabouri st, University of Medical Sciences, Faculty of Pharmacy

City

Tabriz

Province

East Azarbaijan

Postal code

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Not applicable

Data Dictionary

Not applicable